The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kharkhar'ian V.A.

Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I.Pirogova

Korotkiĭ V.N.

State federal facility "Russian State Medical University", Moscow

Usacheva A.Iu.

Rossiĭskaia detskaia klinicheskaia bol'nitsa, Moskva

Dermato-respiratory syndrome: a novel view of the old problem

Authors:

Kharkhar'ian V.A., Korotkiĭ V.N., Usacheva A.Iu.

More about the authors

Read: 2944 times


To cite this article:

Kharkhar'ian VA, Korotkiĭ VN, Usacheva AIu. Dermato-respiratory syndrome: a novel view of the old problem. Russian Journal of Clinical Dermatology and Venereology. 2012;10(3):9‑15. (In Russ.)

Recommended articles:
Search of diagnostic and prognostic biomarkers of immu­noinflammatory dermatoses by means of flow cyto­metry. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):170-177
Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xero­sis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):178-184
Asse­ssment of the serum inte­rleukin 33 (IL-33) level in patients with atopic dermatitis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):293-296
Gene­sis of emollients. Past, present, future. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):412-420
From atopy to infe­ction — a clinical case of combined skin pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):430-436
Atopic dermatitis: the problem of adhe­rence to emollients. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):698-707
Issues of diagnosis and treatment of atopic dermatitis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):838-845
Mechanisms of addi­tivity of physiotherapeutic factors in complex therapy of poly­pous rhinosinusitis complicated by como­rbidities. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(3):5-11

References:

  1. Denisov M.Yu., Kaznacheeva L.F., Molokova A.V., Revyakina V.L. Dermato-respiratornyi sindrom. Allergologiya 2000; 4: 42-44.
  2. Koroleva I.V., Baranov A.A., Balashova E.V. i dr. Obobshchennyi analiz primeneniya monoklonal'nykh antitel k IgE v lechenii bronkhial'noi astmy u detei v RF. Pediatr farmakol 2011; 2: 50-56.
  3. Kulichenko T.V. Omalizumab: rasshirenie vozmozhnostei lecheniya atopicheskikh boleznei. Pediatr farmakol 2009; 3: 36-44.
  4. Lukina O.F., Kulichenko T.V., Torshkhoeva R.M. i dr. Anti-lgE-terapiya tyazheloi bronkhial'noi astmy u detei: dvukhletnii opyt. Pediatr farmakol 2010; 3: 57-65.
  5. Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63: Suppl 86: 8-160.
  6. Cardona I.D., Goleva E., Ou L.S., Leung D.Y. Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes. J Allergy Clin Immunol 2006; 117 : 3: 688-695.
  7. Choi H., Kim S., Kim H.J. et al. Sphingosylphosphorylcholine down-regulates filaggrin gene transcription through NOX5-based NADPH oxidase and cyclooxygenase-2 in human keratinocytes. Biochem Pharmacol 2010; 80: 95-103.
  8. De Benedetto A., Agnihothri R., McGirt L.Y. et al. Atopic dermatitis: a disease caused by innate immune defects? . J Invest Dermatol 2009; 129: 1: 14-30.
  9. Douwes J, Pearce N. Asthma and the westernization "package". Int J Epidemiol 2002; 31: 1098-1102.
  10. Henderson J., Northstone K., Lee S.P. et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy Clin Immunol 2008; 121: 872-877.
  11. Holgate S., Casale T., Wenzel S. et al. The anti-1inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-465.
  12. Ishizaka K., Ishizaka T., Hornbrook M.M. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966; 97: 75-85.
  13. Jackson D.J., Gangnon R.E., Evans M.D. et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008; 78: 667-672.
  14. Johansson S.G., Bieber T., Dahl R. et al. Revised nomtnclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization. J Allergy Clin Immunol 2004; 113: 5: 832-836.
  15. Johansson S.G.O., Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967; 13: 381-394.
  16. Kim B.E., Leung D.Y., Boguniewicz M., Howell M.D. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008; 126: 332-337.
  17. Kim B.E., Leung D.Y., Streib J.E. et al. Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. J Allergy Clin Immunol 2007; 119: 2: 457-463.
  18. Kramer M.S., Matush L., Vanilovich I. et al. Effect of prolonged and exclusive breast feeding on risk of allergy and asthma: cluster randomized trial. BMJ 2007; 335: 7624: 815.
  19. Krathen R.A., Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2006; 53: 338-340.
  20. Kulig M., Bergmann R., Klettke U. et al. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol 1999; 103: 1173-1179.
  21. Lane J.E., Cheyney J.M., Lane T.N. et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68-672.
  22. Liew W.K., Williamson E., Tang M.L. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009; 123: 434-442.
  23. Lin H., Boesel K.M., Griffith D.T. et al. Omalizumab rapidly decreases nasal allergic response and FCεRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
  24. Liu Y.J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006; 203: 269-273.
  25. Malmberg L.P., Saarinen K.M., Pelkonen A.S. et al. Cow's milk allergy as a predictor of bronchial hyperresponsiveness and airway inflammation at school age. Clin Exp Allergy 2010; 40: 1491-1497.
  26. Marenholz I., Nickel R., Rüschendorf F. et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol 2006; 118: 866-871.
  27. Novak N., Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 2005; 53: 171-176.
  28. Ong P.Y., Leung D.Y. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep 2006; 6: 384-389.
  29. Presta L.G., Lahr S.J., Shields R.L. et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-2632.
  30. Ricci G., Patrizi A., Giannetti A. et al. Does improvement management of atopic dermatitis influence the appearance of respiratory allergic diseases? A follow-up study. Clin Mol Allergy 2010; 8: 8.
  31. Spergel J.M. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010; 105: 2: 99-106.
  32. Stemmler S., Parwez Q., Petrasch-Parwez E. et al. Two common loss-of-function mutations within the filaggrin gene predispose for early onset of atopic dermatitis. J Invest Dermatol 2007; 127: 722-724.
  33. Van der Hulst A.E., Klip H., Brand P.L.P. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007; 120: 3: 565-569.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.